Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2017 · 10-Q
Revenue$75.00K$75.00K−44.0% vs Q2 2016 Net Income-$3.23M-$3.23MN/M vs Q2 2016 EPS Diluted-$0.04-$0.04N/M vs Q2 2016 Operating Income-$3,325,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,703,000N/M Margins · derivedOperating margin-4433.3%−2751.2 pt vs Q2 2016
Net margin-4305.3%−2629.2 pt vs Q2 2016
ended Dec 31, 2016 · filed Feb 21, 2017 · 52 d after period end